Sun Pharmaceutical Industries is set to acquire Innovcare Lifesciences in a deal valued at $28.7 million. This strategic move allows Sun Pharma to integrate Innovcare's specialized capabilities into its existing operations. The acquisition is part of a broader effort to strengthen the company's market position and product offerings. By absorbing Innovcare, Sun Pharma aims to enhance its reach within the pharmaceutical sector. The transaction reflects the company's ongoing growth strategy through targeted corporate acquisitions. Financial details indicate a clear investment in expanding their life sciences portfolio. This development is expected to provide synergistic benefits for both entities involved. The deal underscores Sun Pharma's commitment to scaling its operational footprint.